STOCK TITAN

Merck to Participate in the UBS Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Merck (NYSE: MRK) has announced its participation in the upcoming UBS Global Healthcare Conference. The company will be represented by Jannie Oosthuizen, president of Human Health U.S., and Dr. Joerg Koglin, senior vice president and head of general medicine, global clinical development at Merck Research Laboratories. The fireside chat is scheduled for Wednesday, Nov. 13, 2024, at 12:30 p.m. EST / 9:30 a.m. PST. A live audio webcast will be available for investors, analysts, media, and the general public.

Merck (NYSE: MRK) ha annunciato la sua partecipazione alla prossima UBS Global Healthcare Conference. L'azienda sarà rappresentata da Jannie Oosthuizen, presidente della salute umana negli Stati Uniti, e Dr. Joerg Koglin, vicepresidente senior e responsabile della medicina generale, sviluppo clinico globale presso i Merck Research Laboratories. Il colloquio informale è programmato per mercoledì 13 novembre 2024, alle 12:30 EST / 9:30 PST. Sarà disponibile un webcast audio dal vivo per investitori, analisti, media e il pubblico in generale.

Merck (NYSE: MRK) ha anunciado su participación en la próxima Conferencia Global de Salud de UBS. La empresa estará representada por Jannie Oosthuizen, presidenta de Salud Humana en EE. UU., y Dr. Joerg Koglin, vicepresidente senior y jefe de medicina general, desarrollo clínico global en Merck Research Laboratories. La charla se llevará a cabo el miércoles 13 de noviembre de 2024, a las 12:30 p.m. EST / 9:30 a.m. PST. Se ofrecerá una retransmisión de audio en vivo para inversores, analistas, medios de comunicación y el público en general.

머크 (NYSE: MRK)는 다가오는 UBS 글로벌 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사는 제니 오스트하이젠, 미국 인체 건강 대표와 Dr. 요르그 코글린, 머크 연구소의 일반 의학 및 글로벌 임상 개발의 수석 부사장이 대표할 예정입니다. 대화형 정보 세션은 2024년 11월 13일 수요일 오후 12:30 EST / 오전 9:30 PST로 예정되어 있습니다. 투자자, 분석가, 언론 및 일반 대중을 위한 실시간 오디오 웹캐스트가 제공될 것입니다.

Merck (NYSE: MRK) a annoncé sa participation à la prochaine Conférence Mondiale sur la Santé de UBS. L'entreprise sera représentée par Jannie Oosthuizen, présidente de la santé humaine aux États-Unis, et Dr. Joerg Koglin, vice-président senior et responsable de la médecine générale, développement clinique mondial chez Merck Research Laboratories. La discussion informelle est prévue pour le mercredi 13 novembre 2024, à 12h30 EST / 9h30 PST. Une diffusion audio en direct sera disponible pour les investisseurs, analystes, médias et le grand public.

Merck (NYSE: MRK) hat seine Teilnahme an der bevorstehenden UBS Global Healthcare Conference bekannt gegeben. Das Unternehmen wird vertreten durch Jannie Oosthuizen, Präsidentin der Human Health in den USA, und Dr. Joerg Koglin, Senior Vice President und Leiter der Allgemeinmedizin, globale klinische Entwicklung bei Merck Research Laboratories. Der Fireside-Chat ist für Mittwoch, den 13. November 2024, um 12:30 Uhr EST / 9:30 Uhr PST geplant. Eine Live-Audio-Übertragung wird für Investoren, Analysten, Medien und die breite Öffentlichkeit zur Verfügung stehen.

Positive
  • None.
Negative
  • None.

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Joerg Koglin, senior vice president and head of general medicine, global clinical development, Merck Research Laboratories, are scheduled to participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, Nov. 13, 2024, at 12:30 p.m. EST / 9:30 a.m. PST.

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Media Contacts:



Robert Josephson

(203) 914-2372

robert.josephson@merck.com



Michael Levey

(215) 872-1462

michael.levey@merck.com

Investor Contacts:



Peter Dannenbaum

(732) 594-1579

peter.dannenbaum@merck.com



Steven Graziano

(732) 594-1583

steven.graziano@merck.com

Source: Merck & Co., Inc.

FAQ

When is Merck (MRK) presenting at the UBS Global Healthcare Conference 2024?

Merck (MRK) is scheduled to present at the UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 12:30 p.m. EST / 9:30 a.m. PST.

Who will represent Merck (MRK) at the UBS Global Healthcare Conference 2024?

Jannie Oosthuizen, president of Human Health U.S., and Dr. Joerg Koglin, senior vice president and head of general medicine, global clinical development, will represent Merck at the conference.

Can the public access Merck's (MRK) presentation at the UBS Healthcare Conference?

Yes, the public can access a live audio webcast of Merck's presentation through a weblink provided by the company.

Merck & Co., Inc.

NYSE:MRK

MRK Rankings

MRK Latest News

MRK Stock Data

284.13B
2.53B
0.06%
79.34%
1.03%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
KENILWORTH